Quick Take
Inventiva SA (IVA) intends to raise $102 million in an IPO of ADSs representing underlying ordinary shares, according to an amended registration statement.
The company is developing treatments for NASH (Non Alcoholic Steato Hepatitis), MPS (Mucopolysaccharidosis) and other conditions.
IVA is preparing to enter Phase 3 trials for its lead candidate for NASH, a large and quickly growing market.
The IPO appears reasonably valued given the firm's stage and results to-date.
Company & Technology
Daix, France-based Inventiva was founded to advance a pipeline of treatment candidates for various disease conditions